Palantir Faces UK NHS Contract Review as 85% Growth Tests 70-Person Sales Model
Updated
Updated · Trefis · Jun 26
Palantir Faces UK NHS Contract Review as 85% Growth Tests 70-Person Sales Model
1 articles · Updated · Trefis · Jun 26
Summary
Palantir’s UK National Health Service contract is under full review, and a parliamentary committee called the company’s public-sector role an “unacceptable point of weakness.”
That scrutiny lands as Palantir says it cannot meet U.S. demand with a “functionally nonexistent” sales force of about 70 people, raising doubts over whether its deployment-heavy model can scale.
U.S. government revenue still grew 84% year over year, but investors are weighing whether client concentration and political pushback in one allied market could foreshadow broader contract risks.
Margins remain unusually strong—43.7% net and 38.1% operating, both near five-year highs—yet any slowdown or heavier investment could pressure profitability and challenge a stock valued at 49.2 times sales after a 25% 12-month drop.